DaVita Inc. (DVA) 

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DaVita Inc. (“DaVita” or the “Company”) (NYSE: DVA). Investors who purchased DaVita shares are encouraged to obtain additional information and assist the investigation.

          

The investigation concerns whether DaVita violated federal securities laws.

 

On October 28, 2022, DaVita issued a press release disclosing its financial results for the third quarter of 2022.  Among other items, DaVita reported that revenue for the period remained flat from the prior year at $2.9 billion.  Meanwhile, operating income for the period fell roughly 34% year-over-year to $311.8 million, while net income declined roughly 59% year-over-year to $105.4 million as the Company incurred higher than expected costs for center capacity closures following a strategic review of outpatient clinic capacity. On this news, DaVita’s stock price fell sharply during intraday trading on October 28, 2022.

If you are aware of any facts relating to this investigation or purchased DaVita shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.